Molecular Partners AG American Depositary Shares

MOLN XNAS

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

150M

Short interest (Apr 30)

0.0%

Borrow Fee

8.28%

↓ 3.5%

Available Shares

70K

↓ 44.1%

Price Chart

Company Overview

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.

Company Info

Exchange: NASDAQ

CIK: 0001745114

Asset Type: ADRC

Market Data

Market Cap: $147,043,758

Employees: 134

Status: Active

Short Interest

Current Borrow Fee 8.28%

Range: 8.28% - 9.08%

Available Shares 70K

Range: 30K - 65K

Recent Changes

Fee Change: ↓ 5.6%

Available Change: ↓ 3.6%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime